News und Analysen
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Savara
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA).
Faruqi & Faruqi is a leading
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine ratio (UACR) from
EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
EQS-News: Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
EQS-News: Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
EQS-News: Immunic to Participate in Industry and Investor Conferences in November
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1)
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
Bayer will present methods and baseline characteristic data from the global Phase III OCEANIC-STROKE study with the investigational agent asundexian, in a late-breaking presentation at the upcoming
EQS-News: Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
EQS-News: Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced positive 36-month data from exPDite, a Phase I
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member